



## Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)

**Mechelen, Belgium, 28 November 2016** – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 22 November 2016 (the 'Notification'), indicating that the shareholding of DHAM NV (which is controlled by KORYS NV, which is in turn controlled by Stichting Administratiekantoor Cozin) has decreased below the 3% notification threshold.

The Notification contains the following information:

- **Reason for the Notification:** passive downward crossing of the lowest threshold.
- **Notification by:** a parent undertaking or a controlling person.
- **Persons subject to the notification requirement:** DHAM NV, G. Gezellestraat 126, 1654 Huizingen, Belgium, KORYS NV, G. Gezellestraat 126, 1654 Huizingen, Belgium and Stichting Administratiekantoor Cozin, Claude Debussylaan 24, 1085 MD Amsterdam, The Netherlands.
- **Transaction date:** 17 November 2016.
- **Threshold that is crossed:** 3%.
- **Denominator:** 44,648,105.
- **Chain of controlled undertakings through which the holding was effectively held:**  
DHAM NV is controlled by KORYS NV, which is controlled by Stichting Administratiekantoor Cozin. Stichting Administratiekantoor Cozin is not a controlled entity.

The Notification is available [here](#) on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

----- END -----

**More information:**

Renate Degrave

Manager Corporate Communications & Investor Relations

e-mail [rdegrave@biocartis.com](mailto:rdegrave@biocartis.com)

tel +32 15 631 729

mobile +32 471 53 60 64

[@Biocartis](https://twitter.com/Biocartis)

[www.linkedin.com/Biocartis](https://www.linkedin.com/Biocartis)

**About Biocartis**

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests on the market. More information: [www.biocartis.com](http://www.biocartis.com). Press Photo Library available [here](#). Follow us on [Twitter](https://twitter.com/Biocartis_): @Biocartis\_.